Research Analysts Issue Forecasts for Ovid Therapeutics Inc’s Q1 2018 Earnings (OVID)
Ovid Therapeutics Inc (NASDAQ:OVID) – Research analysts at William Blair issued their Q1 2018 earnings per share estimates for shares of Ovid Therapeutics in a report issued on Wednesday. William Blair analyst T. Lugo forecasts that the company will earn ($0.48) per share for the quarter. William Blair also issued estimates for Ovid Therapeutics’ Q2 2018 earnings at ($0.54) EPS, Q3 2018 earnings at ($0.59) EPS and Q4 2018 earnings at ($0.58) EPS.
Separately, Zacks Investment Research upgraded Ovid Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Five equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $19.33.
Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.16.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new position in shares of Ovid Therapeutics in the second quarter worth $135,000. TIAA CREF Investment Management LLC bought a new position in shares of Ovid Therapeutics in the second quarter worth $142,000. Schwab Charles Investment Management Inc. bought a new position in shares of Ovid Therapeutics in the second quarter worth $153,000. OxFORD Asset Management LLP bought a new position in shares of Ovid Therapeutics in the second quarter worth $189,000. Finally, Citadel Advisors LLC bought a new position in shares of Ovid Therapeutics in the second quarter worth $204,000. Institutional investors own 29.36% of the company’s stock.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Receive News & Stock Ratings for Ovid Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics Inc and related stocks with our FREE daily email newsletter.